| 杨大春马双陶李秀川杨永健李德唐兵.罗格列酮对2型糖尿病合并急性冠脉综合征患者血清TGF-β1及IL-1β
的影响[J].现代生物医学进展英文版,2011,11(21):4087-4089. |
| 罗格列酮对2型糖尿病合并急性冠脉综合征患者血清TGF-β1及IL-1β
的影响 |
| Effects of Rosiglitazone on Serum Levels of TGF-β1 and IL-1βin Patientswith Type 2 Diabetes Mellitus and Acute Coronary Syndrome |
| |
| DOI： |
| 中文关键词: 糖尿病 冠状动脉疾病 过氧化物酶体增殖物激活受体 罗格列酮 炎症介质 抗炎因子 |
| 英文关键词: Type 2 diabetes mellitus Coronary artery disease Peroxisome proliferator-activated receptors Rosiglitazone Inflammatory
mediators |
| 基金项目:成都军区十一·五科研面上项目(第二批)（MB09023） |
|
| Hits: 840 |
| Download times: 810 |
| 中文摘要: |
| 目的：观察罗格列酮对2 型糖尿病合并急性冠脉综合征患者血清转化生长因子-β1 (TGF-β1)及白细胞介素-1β(IL-1β)
的影响。方法：116例2 型糖尿病合并急性冠脉综合征患者，随机分为罗格列酮治疗组(n=58)和常规治疗组(n=58)。检测两组患者
治疗前后空腹血糖、血脂及血清TGF-β1、IL-1β的变化。结果：治疗前两组患者空腹血糖、血脂及血清TGF-β1、IL-1β的水平无
显著差异(P＞0.05)；治疗4月后，两组患者空腹血糖、血脂无显著差异，血清IL-1β 较治疗前下降(P＜0.01)，罗格列酮组较常规治
疗组下降明显，两组间差异显著(P＜0.05)；治疗后血清TGF-β1 较治疗前上升(P＜0.05)，罗格列酮组与常规治疗组比较，差异显
著(P＜0.05)。结论：罗格列酮能调控糖尿病合并急性冠脉综合征患者炎症介质和抗炎因子的分泌，可能具有改善动脉粥样硬化的
作用。 |
| 英文摘要: |
| Objectives: To explore the effects of rosiglitazone on serum levels of transforming growth factor-β1 (TGF-β1) and
interleukin-1β (IL-1β) in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS). Methods: 116 patients
with T2DM and ACS were randomly divided into rosiglitazone group (n=58) and control group (n=58). Fasting plasma glucose (FPG),
plasma lipids, serum TGF-β1 and IL-1β of the patients were measured at baseline and after 4-month treatment. Results: At baseline,
FPG, plasma lipids, serum TGF-β1 and IL-1β were similar between the two groups (all P>0.05). After 4-month treatment, serum
IL-1β levels in the two groups were significantly decreased (P<0.01) while serum TGF-β1 levels were significantly increased (P<0.05).
Moreover, the changes in serum TGF-β1 and IL-1βwere enhanced (both P<0.05) in rosiglitazone group compared with control group.
Additionally, serum TGF-β1 and IL-1β levels after treatment were similar between the two groups. Conclusion: Rosiglitazone may regulate
the releases of inflammatory mediator and anti- inflammatory factor and consequently ameliorate atherosclerosis in patients with
T2DM and ACS. |
|
View Full Text
View/Add Comment Download reader |
| Close |
